Neuropharm set to sign fluoxetine autism deal
This article was originally published in Scrip
Executive Summary
Neuropharm is currently in discussions with a third-party pharmaceutical company for a potential collaboration on the further development and commercialisation of its lead product candidate NPL-2008.